Purpose: To investigate the incidence of ocular hypertension (OHT) following suprachoroidal injection of triamcinolone acetonide (SCS-TA) for non-infectious uveitic macular edema.
Methods: Retrospective review of eyes undergoing SCS-TA. The primary outcome was incidence of OHT (IOP > 24 mm Hg). Secondary outcomes included incidence of IOP > 30 mmHg, IOP rise ≥10 mm Hg above baseline, and treatment for OHT.
Results: 76 eyes of 70 patients were treated with a mean of 1.71 (range 1-5) SCS-TA injections with an average follow-up of 7.6 (range 3.0-14.9) months. 9 eyes (11.8%) developed OHT, 4 eyes (5.3%) had IOP > 30 mmHg, and 9 eyes (11.8%) had an IOP elevation of ≥ 10 mmHg above baseline at any point after their first injection. Eyes that developed OHT were treated with topical therapy (7 eyes, mean 1.9 agents, range 1-4 agents) or close observation (2 eyes). No eyes required incisional glaucoma surgery. Eyes with history of glaucoma or OHT (7/34, 20.1%) were more likely to develop OHT versus eyes with no history (2/42, 4.8%, p = 0.03).
Conclusion: In this real-world cohort, SCS-TA was associated with a low-incidence of OHT, consistent with clinical trial data. A prior history of glaucoma or OHT is a significant association for developing OHT following SCS-TA.
Keywords: Suprachoroidal space; Suprachoroidal triamcinolone acetonide; Uveitis; ocular hypertension; uveitic macular edema.